New Marker of Heart Failure Outcomes: Galectin-3

Moderator:

Discussants:

  • Date: October 23, 2012
    Roundtable ID: CV15561
    Citation: Published online first.
  • Summary:

    Dr. W. Frank Peacock from the Baylor College of Medicine moderated the topic "New Marker of Heart Failure Outcomes: Galectin-3" with Drs. Rudolf de Boer from University Medical Center Groningen, Salvatore Di Somma from San Andrea Hospital, University Sapienza, and Alan Maisel from the University of California—San Diego, participating.

    The discussion focused primarily on:

    1. An overview of what is known about the use of galectin-3 as a biomarker in heart failure;
    2. an assessment of how galectin-3 can be applied in clinical practice by emergency department physicians;
    3. implications of galectin-3 levels for cardiological follow-up and heart failure patient management; and
    4. how the use of galectin-3 as a biomarker can be applied to prevent progression of heart failure.

    (Med Roundtable Cardiovasc Ed. 2013;4(1):e46–e53)

    ©2013 FoxP2Media, LLC

  • Compounds:
    No compounds discussed.
    Trials:
    • COACH
    • Framingham Offspring Study
    • RALES
    • EPHESUS
    • EMPHASIS-HF
    • ACTIVATE
    • REGAL
    • MADIT-CRT

You are not authorized to access this content.

You are not authorized to access this content.
You are not authorized to access this content.
Please subscribe to use our print features or to download PDF files.